The global precision oncology market size is expected to reach USD 202.0 billion and expand at a CAGR of 9.7% from 2023 to 2030. Precision oncology is a growing field where the market products emphasize on molecular profiling of tumors to identify alterations in the gene. Currently, the industry has witnessed major success with a 95% response rate being observed in patients along with extended quality-adjusted life. The market products offer the potential for improved patient care and a better-informed decision-making experience in hospitals and clinics. Alternatively, the increasing prevalence of cancer across the globe, the rising number of clinical trial studies, and the rapid adoption of technology in precision oncology diagnostic is anticipated to boost the market demand.
Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.
In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna’s TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.
Due to the COVID-19 pandemic, the precision oncology market had a huge impact as the pandemic exaggerated healthcare across the globe for people living with cancer, possessing a unique set of challenges. Besides, delayed diagnosis and therapeutics using precision oncology have affected cancer patient diagnosis and treatment to a major extent. However, post-COVID-19 pandemic, the market has gained rapid demand as precision oncology offers better therapeutic outcomes and improves the quality of patient life for cancer patients.
In January 2022, OncXerna Therapeutics, Inc. and Exact Sciences Corp. mentioned the agreement to introduce OncXerna’s TME Panel lab services for patients in the U.S. It is an innovative gene expression score, which helps identify patients to respond to immunotherapies and anti-angiogenic. Further, the company added that it believes to provide clinician access to the Xerna TME Panel through biopharma partners as a companion diagnostic and existing precision oncology team.
Precision Oncology Market Report Highlights
- Based on product type, the therapeutics segment held the majority of the market share of around 71.7% in 2022 attributed to its rising number of approvals of therapies has benefited the market demand
- Based on cancer type, the breast cancer segment dominated the market in terms of revenue share in 2022 owing to the rising incidence of breast cancer, expanding research activities, evolved diagnostics, and overall patient prognosis is likely to drive the market
- Based on end-use, the hospitals & clinics segment accounted for the largest market share of around 46.8% in 2022 owing to the growing focus on components such as precision planning, precise diagnosis and monitoring, precise treatment
- In 2022, North America dominated the market in terms of revenue with a share of around 42.5% due to trending factors such as rising healthcare expenditure, and evolving healthcare landscape, changing competitive landscape of the precision oncology market in U.S. and Canada
Table of Contents
Chapter 1 Report Scope and Objectives1.1 Market Segmentation & Scope
1.2 Regional Scope
1.2.1 Estimates And Forecast Timeline
1.3 Objectives
1.3.1 Objective - 1
1.3.2 Objective - 2
1.3.3 Objective - 3
Chapter 2 Methodology
2.1 Research Methodology
2.2 Information Procurement
2.2.1 Purchased Database
2.2.2 Internal Database
2.2.3 Secondary Sources
2.2.4 Primary Research
2.3 Information Or Data Analysis
2.3.1 Data Analysis Models
2.4 Market Formulation & Validation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.5.2 Volume Price Analysis (Model 2)
2.6 List Of Secondary Sources
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Product Type
3.2.2 Cancer Type
3.2.3 End-Use
3.2.4 Region
3.3 Competitive Insights
3.4 Precision Oncology Market Outlook, 2020
Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Ancillary Market Outlook
4.2 Precision Oncology Market Dynamics
4.2.1 Market Driver Analysis
4.2.2 Market Restraint Analysis
4.3 Precision Oncology Market: Business Environment Analysis Tools
4.3.1 Porter’s Five Forces Analysis
4.3.2 Threat Of New Entrants
4.3.3 Bargaining Power Of Suppliers
4.3.4 Bargaining Power Of Buyers
4.3.5 Competitive Rivalry
4.3.6 Threat Of Substitutes
4.3.7 Pestel Analysis
4.3.7.1 Political & Legal Landscape
4.3.7.2 Economic Landscape
4.3.7.3 Technological Landscape
4.4 Penetration & Growth Prospect Mapping
4.5 Impact Of Covid-19 On Precision Oncology Market
Chapter 5 Precision Oncology Market: Product Type Analysis
5.1 Precision Oncology Market Share Analysis, 2020 & 2028
5.2 Precision Oncology Market: Segment Dashboard:
5.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Product Type Segment
5.3.1 Diagnostics
5.3.1.1 Diagnostics Market, 2018 - 2030 (USD Million)
5.3.2 Therapeutics
5.3.2.1 Therapeutics Market, 2018 - 2030 (USD Million)
Chapter 6 Precision Oncology Market: Cancer Type Analysis
6.1 Precision Oncology Cancer Type Market Share Analysis, 2020 & 2028
6.2 Precision Oncology Cancer Type Market: Segment Dashboard:
6.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Cancer Type Segment
6.3.1 Breast Cancer
6.3.1.1 Breast Cancer Market, 2018 - 2030 (USD Million)
6.3.2 Colorectal Cancer
6.3.2.1 Colorectal Cancer Market, 2018 - 2030 (USD Million)
6.3.3 Cervical Cancer
6.3.4 Cervical Cancer Market, 2018 - 2030 (USD Million)
6.3.5 Prostate Cancer
6.3.5.1 Prostate Cancer Market, 2018 - 2030 (USD Million)
6.3.6 Lung Cancer
6.3.6.1 Lung Cancer Market, 2018 - 2030 (USD Million)
6.3.7 Others Cancer
6.3.7.1 Others Cancer Market, 2018 - 2030 (USD Million)
Chapter 7 Precision Oncology Market: End-Use Analysis
7.1 Precision Oncology End-Use Market Share Analysis, 2020 & 2028
7.2 Precision Oncology End-Use Market: Segment Dashboard:
7.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The End-Use Segment
7.3.1 Hospitals & Diagnostic Laboratories
7.3.2 Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
7.3.3 Pharmaceutical & Biotechnology Companies
7.3.3.1 Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
7.3.4 Healthcare Data Companies
7.3.5 Healthcare Data Companies Market, 2018 - 2030 (USD Million)
Chapter 8 Precision Oncology Market: Regional Analysis
8.1 Precision Oncology Regional Market Share Analysis, 2020 & 2028
8.2 Regional Market Snapshot
8.3 North America
8.3.1 North America Precision Oncology Market, 2018 - 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. Precision Oncology Market, 2018 - 2030 (USD Million)
8.3.3 Canada
8.3.3.1 Canada Precision Oncology Market, 2018 - 2030 (USD Million)
8.4 Europe
8.4.1 Europe Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.2 U.K.
8.4.2.1 U.K. Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.3 Germany
8.4.3.1 Germany Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.4 France
8.4.4.1 France Precision Oncology Market, 2018 - 2030 (USD MILLION)
8.4.5 Italy
8.4.5.1 Italy Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.6 Spain
8.4.6.1 Spain Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.7 Denmark
8.4.8 Denmark Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.9 Sweden
8.4.10 Sweden Precision Oncology Market, 2018 - 2030 (USD Million)
8.4.11 Norway
8.4.12 Norway Precision Oncology Market, 2018 - 2030 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.2 Japan
8.5.2.1 Japan Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.3 China
8.5.3.1 China Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.4 India
8.5.4.1 India Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.5 Australia
8.5.5.1 Australia Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.6 Thailand
8.5.7 Thailand Precision Oncology Market, 2018 - 2030 (USD Million)
8.5.8 South Korea
8.5.8.1 South Korea Precision Oncology Market, 2018 - 2030 (USD Million)
8.6 Latin America
8.6.1 Latin America Precision Oncology Market, 2018 - 2030 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil Precision Oncology Market, 2018 - 2030 (USD Million)
8.6.3 Mexico
8.6.3.1 Mexico Precision Oncology Market, 2018 - 2030 (USD Million)
8.6.4 Argentina
8.6.4.1 Argentina Precision Oncology Market, 2018 - 2030 (USD Million)
8.7 Middle East And Africa (Mea)
8.7.1 Mea Precision Oncology Market, 2018 - 2030 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa Precision Oncology Market, 2018 - 2030 (USD Million)
8.7.3 Saudi Arabia
8.7.3.1 Saudi Arabia Precision Oncology Market, 2018 - 2030 (USD Million)
8.7.4 UAE
8.7.4.1 UAE Precision Oncology Market, 2018 - 2030 (USD Million)
8.7.5 Kuwait
8.7.6 Kuwait Precision Oncology Market, 2018 - 2030 (USD Million)
Chapter 9 Competitive Analysis
9.1 Recent Developments & Impact Analysis, By Key Market Participants
9.2 Company Profiles
9.2.1 THERMO FISHER SCIENTIFIC INC.
9.2.1.1 Company overview
9.2.1.2 Financial performance
9.2.1.3 Product Benchmarking
9.2.1.4 Strategic initiatives
9.2.2 INVITAE CORPORATION
9.2.2.1 Company overview
9.2.2.2 Product Benchmarking
9.2.2.3 Strategic initiatives
9.2.3 QIAGEN N.V.
9.2.3.1 Company overview
9.2.3.2 Product Benchmarking
9.2.3.3 Strategic initiatives
9.2.4 ILLUMINA, INC.
9.2.4.1 Company overview
9.2.4.2 Product Benchmarking
9.2.4.3 Strategic initiatives
9.2.5 LABORATORY CORPORATION OF AMERICA HOLDING
9.2.5.1 Company overview
9.2.5.2 Product Benchmarking
9.2.5.3 Strategic initiatives
9.2.6 EXACT SCIENCES CORPORATION
9.2.6.1 Company overview
9.2.6.2 Product Benchmarking
9.2.6.3 Strategic initiatives
9.2.7 RAIN ONCOLOGY INC.
9.2.7.1 Company overview
9.2.7.2 Product Benchmarking
9.2.7.3 Strategic initiatives
9.2.8 STRATA ONCOLOGY, INC.
9.2.8.1 Company overview
9.2.8.2 Product Benchmarking
9.2.8.3 Strategic initiatives
9.2.9 XILIS, INC.
9.2.9.1 Company overview
9.2.9.2 Product Benchmarking
9.2.9.3 Strategic initiatives
9.2.10 VARIANTYX, INC.
9.2.10.1 Company overview
9.2.10.2 Product Benchmarking
9.2.10.3 Strategic initiatives
9.2.11 BIOSERVE
9.2.11.1 Company overview
9.2.11.2 Product Benchmarking
9.2.11.3 Strategic initiatives
9.2.12 RELAY THERAPEUTICS
9.2.12.1 Company overview
9.2.12.2 Product Benchmarking
9.2.12.3 Strategic initiatives
9.2.13 ACRIVON THERAPEUTICS
9.2.13.1 Company overview
9.2.13.2 Product Benchmarking
List of Tables
Table 1 List of secondary product types
Table 2 North America precision oncology estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 3 North America precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 4 North America precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 5 North America precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 6 U.S. precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 7 U.S. precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 8 U.S. precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 9 Canada precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 10 Canada precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 11 Canada precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 12 Europe precision oncology estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 13 Europe precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 14 Europe precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 15 Europe precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 16 U.K. precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 17 U.K. precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 18 U.K. precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 19 Germany precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 20 Germany precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 21 Germany precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 22 France precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 23 France precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 24 France precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 25 Italy precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 26 Italy Precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 27 Italy precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 28 Spain precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 29 Spain precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 30 Spain precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 31 Denmark precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 32 Denmark precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 33 Denmark precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 34 Sweden precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 35 Sweden precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 36 Sweden precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 37 Norway precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 38 Norway precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 39 Norway precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 40 Asia Pacific precision oncology estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 41 Asia Pacific precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 42 Asia Pacific precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 43 Asia Pacific precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 44 Japan precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 45 Japan precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 46 Japan precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 47 China precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 48 China precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 49 China precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 50 India precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 51 India precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 52 India precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 53 Australia precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 54 Australia precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 55 Australia precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 56 South Korea precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 57 South Korea precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 58 South Korea precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 59 Latin America precision oncology estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 60 Latin America precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 61 Latin America precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 62 Latin America precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 63 Brazil precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 64 Brazil precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 65 Brazil precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 66 Mexico precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 67 Mexico precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 68 Mexico precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 69 Argentina precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 70 Argentina precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 71 Argentina precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 72 MEA precision oncology estimates and forecasts, by country, 2017 - 2030 (USD Million)
Table 73 MEA precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 74 MEA precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 75 MEA precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 76 South Africa precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 77 South Africa precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 78 South Africa precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 79 Saudi Arabia precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 80 Saudi Arabia precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 81 Saudi Arabia precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 82 UAE precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 83 UAE precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 84 UAE precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
Table 85 Kuwait precision oncology estimates and forecasts, by product type, 2017 - 2030 (USD Million)
Table 86 Kuwait precision oncology estimates and forecasts, by cancer type, 2017 - 2030 (USD Million)
Table 87 Kuwait precision oncology estimates and forecasts, by end-use, 2017 - 2030 (USD Million)
List of Figures
Fig. 1 Precision oncology market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain based sizing & forecasting
Fig. 7 QFD modelling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 Precision oncology market outlook, 2020 (USD Million)
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Penetration & growth prospect mapping
Fig. 14 Precision oncology market share analysis, 2020 & 2028 (USD Million)
Fig. 15 Precision oncology market: Segment dashboard
Fig. 16 Diagnostics market, 2018 - 2030 (USD Million )
Fig. 17 Therapeutics Market, 2018 - 2030 (USD Million)
Fig. 18 Precision oncology cancer type market share analysis, 2020 & 2028 (USD Million)
Fig. 19 Precision oncology cancer type market: Segment dashboard
Fig. 20 Breast cancer market, 2018 - 2030 (USD Million)
Fig. 21 Colorectal cancer market, 2018 - 2030 (USD Million)
Fig. 22 Cervical cancer market, 2018 - 2030 (USD Million)
Fig. 23 Prostate cancer market, 2018 - 2030 (USD Million)
Fig. 24 Lung cancer market, 2018 - 2030 (USD Million)
Fig. 25 Others market, 2018 - 2030 (USD Million)
Fig. 26 Precision oncology end-use market share analysis, 2020 & 2028 (USD Million)
Fig. 27 Precision oncology end-use market: Segment dashboard
Fig. 28 Hospitals & diagnostic laboratories market, 2018 - 2030 (USD Million)
Fig. 29 Pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
Fig. 30 Healthcare data companies market, 2018 - 2030 (USD Million)
Fig. 31 Precision oncology regional market share analysis, 2020 & 2028 (USD Million)
Fig. 32 Regional market place: Key takeaways
Fig. 33 North America precision oncology market, 2018 - 2030 (USD Million)
Fig. 34 U.S. precision oncology market, 2018 - 2030 (USD Million)
Fig. 35 Canada precision oncology market, 2018 - 2030 (USD Million)
Fig. 36 Europe precision oncology market, 2018 - 2030 (USD Million)
Fig. 37 U.K. precision oncology market, 2018 - 2030 (USD Million)
Fig. 38 Germany precision oncology market, 2018 - 2030 (USD Million)
Fig. 39 France precision oncology market, 2018 - 2030 (USD Million)
Fig. 40 Italy precision oncology market, 2018 - 2030 (USD Million)
Fig. 41 Spain precision oncology market, 2018 - 2030 (USD Million)
Fig. 42 Denmark precision oncology market, 2018 - 2030 (USD Million)
Fig. 43 Sweden precision oncology market, 2018 - 2030 (USD Million)
Fig. 44 Norway precision oncology market, 2018 - 2030 (USD Million)
Fig. 45 Asia Pacific precision oncology market, 2018 - 2030 (USD Million)
Fig. 46 Japan precision oncology market, 2018 - 2030 (USD Million)
Fig. 47 China precision oncology market, 2018 - 2030 (USD Million)
Fig. 48 India precision oncology market, 2018 - 2030 (USD Million)
Fig. 49 Australia precision oncology market, 2018 - 2030 (USD Million)
Fig. 50 Thailand precision oncology market, 2018 - 2030 (USD Million)
Fig. 51 South Korea precision oncology market, 2018 - 2030 (USD Million)
Fig. 52 Latin America precision oncology market, 2018 - 2030 (USD Million)
Fig. 53 Brazil precision oncology market, 2018 - 2030 (USD Million)
Fig. 54 Mexico precision oncology market, 2018 - 2030 (USD Million)
Fig. 55 Argentina precision oncology market, 2018 - 2030 (USD Million)
Fig. 56 MEA precision oncology market, 2018 - 2030 (USD Million)
Fig. 57 South Africa precision oncology market, 2018 - 2030 (USD Million)
Fig. 58 Saudi Arabia precision oncology market, 2018 - 2030 (USD Million)
Fig. 59 UAE precision oncology market, 2018 - 2030 (USD Million)
Fig. 56 Kuwait precision oncology market, 2018 - 2030 (USD Million)
Fig. 58 Strategy framework
Companies Mentioned
- THERMO FISHER SCIENTIFIC INC.
- INVITAE CORPORATION
- QIAGEN N.V.
- ILLUMINA, INC.
- LABORATORY CORPORATION OF AMERICA HOLDING
- EXACT SCIENCES CORPORATION
- RAIN ONCOLOGY INC.
- STRATA ONCOLOGY, INC.
- XILIS, INC.
- VARIANTYX, INC.
- BIOSERVE
- RELAY THERAPEUTICS
- ACRIVON THERAPEUTICS
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 96.4 Billion |
| Forecasted Market Value ( USD | $ 202 Billion |
| Compound Annual Growth Rate | 9.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
